Scholar Rock Holding Corp
SRRKHealthcare|Biotechnology|USA
$56.75
-1.26 (-2.17%)
Tangible Book
$2.32
Earnings Power
$2.96
Clinical Trials (10)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05626855 Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab | Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3 | P3 | Active | 238 | Open-label | Apitegromab |
| NCT07047144 A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy | Spinal Muscular Atrophy, SMA | P2 | Recruiting | 52 | RCT, Double-blind | Apitegromab, Nusinersen, Risdiplam |
| NCT07444294 A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy Adults | Healthy | P1 | Recruiting | 76 | RCT, Double-blind | Placebo, SRK-439, SRK-439 |
| NCT06419322 Acceptability, Feasibility, Safety and Efficacy of a Optimized Rehabilitation Program for Treated Patients With Spinal Muscular Atrophy (SMA). | Spinal Muscular Atrophy | N/A | Active | 14 | Open-label | — |
| NCT05156320 Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam | Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3 | P3 | Completed | 188 | RCT, Double-blind | Apitegromab, Placebo |
| NCT07435129 Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD | Facioscapulohumeral Muscular Dystrophy, FSHD | P2 | Not Yet Recruiting | 60 | RCT, Double-blind | Apitegromab, Placebo |
| NCT03921528 An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy | Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3 | P2 | Completed | 58 | RCT, Open-label | SRK-015 |
| NCT06445075 Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese | Overweight and Obesity | P2 | Completed | 102 | RCT, Double-blind | Apitegromab, Placebo, Tirzepatide |
| NCT04291079 SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON) | Cancer | P1 | Completed | 112 | Open-label | SRK-181, anti-PD-(L)1 antibody therapy |
| NCT06877689 EAP of Apitegromab for Patients With Spinal Muscular Atrophy | SMA | NO_LONGER_AVAILABLE | — | — | Apitegromab |